万泰生物(603392) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was RMB 752,512,644.03, a decrease of 73.93% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2024 was RMB 125,708,151.18, down 89.90% year-on-year[5] - The diluted earnings per share for Q1 2024 was RMB 0.10, reflecting a decline of 89.98% compared to the previous year[2] - Total revenue for Q1 2024 was ¥752,512,644.03, a significant decrease of 73.9% compared to ¥2,886,602,037.70 in Q1 2023[28] - Net profit for Q1 2024 was ¥129,783,656.69, a decrease of 89.6% compared to ¥1,252,742,514.19 in Q1 2023[29] - The basic and diluted earnings per share for Q1 2024 are both ¥0.10, down from ¥0.99 in Q1 2023[30] Assets and Liabilities - Total assets at the end of Q1 2024 were RMB 15,555,282,837.10, a decrease of 1.02% from the end of the previous year[7] - Cash and cash equivalents as of March 31, 2024, were ¥3,768,033,878.52, a slight decrease from ¥3,818,318,679.35 at the end of 2023[20] - Total assets as of March 31, 2024, amounted to ¥15,555,282,837.10, down from ¥15,714,997,884.50 at the end of 2023[27] - Total liabilities decreased to ¥2,551,837,463.14 as of March 31, 2024, from ¥2,831,340,634.47 at the end of 2023[25] - The company reported a decrease in accounts receivable to ¥2,859,861,403.85 from ¥2,990,889,287.05 at the end of 2023[20] - The company’s inventory as of March 31, 2024, was ¥853,991,361.24, down from ¥905,484,973.00 at the end of 2023[20] - The company’s total equity increased to ¥13,003,445,373.96 as of March 31, 2024, from ¥12,883,657,250.03 at the end of 2023[27] Cash Flow - The net cash flow from operating activities was RMB 9,280,280.41, not applicable due to reduced business promotion expenses[1] - Cash inflow from operating activities for Q1 2024 is ¥952,130,996.74, a decrease from ¥1,705,154,373.92 in Q1 2023[32] - The net cash flow from operating activities for Q1 2024 is ¥9,280,280.41, compared to a net outflow of ¥313,683,356.17 in Q1 2023[32] - Cash outflow from investing activities for Q1 2024 is ¥2,726,893,343.28, up from ¥1,623,326,983.99 in Q1 2023[33] - The net cash flow from investing activities for Q1 2024 is -¥53,959,616.82, compared to -¥481,231,342.96 in Q1 2023[33] - Cash inflow from financing activities for Q1 2024 is ¥32,785,000.00, compared to ¥25,519,500.00 in Q1 2023[33] - The net cash flow from financing activities for Q1 2024 is -¥5,765,079.91, compared to -¥23,898,209.58 in Q1 2023[33] - The ending cash and cash equivalents balance for Q1 2024 is ¥3,733,402,004.24, down from ¥4,363,296,353.63 in Q1 2023[33] Research and Development - Research and development expenses for Q1 2024 were ¥206,734,939.77, slightly down from ¥217,843,428.15 in Q1 2023[29] Market Strategy - The company plans to adjust its market strategy to focus on differentiated advantages and explore new sales systems to maintain market share[15] - The company is actively expanding into overseas markets and collaborating with international organizations to gain market access[15] Non-Recurring Gains - Non-recurring gains included government subsidies amounting to RMB 46,141,125.04[11]